HRMY — HARMONY BIOSCIENCES HLDGS IN
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About HARMONY BIOSCIENCES HLDGS IN (HRMY)
HARMONY BIOSCIENCES HLDGS IN (HRMY) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $27M. Across recent filings, tracked investors recorded 1 new positions, 2 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in HRMY
How many top investors track HRMY
A small number of top investors own this.
HRMY Ownership Composition
How HARMONY BIOSCIENCES HLDGS IN is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting HRMY
- Izzy EnglanderMar 31, 2026Millennium ManagementShares954.4KValue$26.7M% Portfolio0.01%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares677.6KValue$19M% Portfolio0.00%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares251.5KValue$7M% Portfolio0.03%
Recent activity
- Increased$7M(10.06%)May 15, 2026
- Increased$8.6M(8.03%)Feb 13, 2026
- New$5.8MNov 13, 2025
Frequently asked questions
- How many institutional investors hold HRMY?
- 3 tracked institutional investors disclosed a position in HRMY (HARMONY BIOSCIENCES HLDGS IN) in their most recent 13F filing.
- Who is the largest institutional holder of HRMY?
- Izzy Englander, Millennium Management, holds the largest disclosed position in HRMY, valued at $27M.
- Did institutional ownership of HRMY increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 2 increased, 0 reduced, and 0 fully exited HRMY.
- Where does this HRMY ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.